[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"BonusBio Group Ltd\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":68},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100287618","phase-1-enhancement-of-bone-regeneration-and-healing-in-the-extremities-by-the-use-of-autologous-bonofill-ii-100287618",false,"NCT03024008","Enhancement of Bone Regeneration and Healing in the Extremities by the Use of Autologous BonoFill-II","A Multicenter Study to Evaluate the Enhancement of Bone Regeneration and Healing in the Extremities by the Use of Autologous BonoFill-II","Inclusion Criteria:\n\n* Long and short bones extra articular comminuted fracture or\n* Long and short bones extra and intra articular defect\u002Fgap or non union, incapable of self-regeneration\n\nExclusion Criteria:\n\n* Age is under 18 or above 80\n* A simple fracture manageable by one definitive treatment\n* Pregnant or lactating women\n* Patients with active infection that is in question and needs osteogenic treatment.\n* More than 3 previous failed interventions at the surgical site\n* History of advanced congestive heart failure or active acute myocardial infarction (AMI), renal failure (estimated GFR of \\\u003C30 ml\u002Fmin\u002F1.73 m2 at screening), or hepatic disease (hepatic insufficiency classified as Child-Pugh B or C)\n* Diabetic subjects (HbA1c \\> 8)\n* Subject treated currently with systemic steroids.\n* Subjects with known autoimmune diseases, such as Addison's disease, Celiac disease - sprue (gluten-sensitive enteropathy), Dermatomyositis, Graves disease, Hashimoto's thyroiditis, Multiple sclerosis, Myasthenia gravis, Pernicious anemia, Reactive arthritis, Rheumatoid arthritis, Sjogren syndrome, Systemic lupus erythematosus.\n* Subjects diagnosed with osteoporosis\n* Chronic severe PVD (Peripheral Vascular Disease) subjects\n* Post major vascular operation in the treated limb\u002Fs and above the surgical site (with or without Gore-Tex grafting)\n* Subjects that have a known scar healing problem (keloid formation).\n* Subjects treated with Bisphosphonate drugs\n* Oncology patient or subjects who received chemotherapy or radiotherapy treatment in the past 12 months\n* Immunocompromised condition from any reason, at screening\n* Subjects participating in another clinical trial 30 days prior to and during the study period.\n* Drug addicts and psychiatric patients patients incapable of giving consent.\n* Subjects with a known history of any significant medical disorder, which in the investigator's judgment contraindicates the subject's participation\n* Subjects with any known allergy for local\u002Fgeneral anesthesia\n* Positive serology for either HIV, hepatitis B or hepatitis C\n* Abnormal clinically significant laboratory test and findings, as per the investigator's judgment","ALL","18 Years","80 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","The purpose of this clinical study is to evaluate the safety and the efficacy of BonoFill-II as an autologous bone-regenerating graft in the reconstruction of deficient bone in two clinical indications:\n\n1. Long and short bone extra-articular comminuted fracture\n2. Long and short bones extra and intra articular defect \u002FGap or non-union, incapable of self-regeneration",[28],"Bone Fracture",[30,31,32],"Critical Gap","Comminuted Fracture","Extra-Articular","RECRUITING","2025-12-03",{"date":36,"type":37},"2025-12-10","ACTUAL",{"date":39,"type":37},"2017-07-27",{"date":41,"type":21},"2027-06",{"name":43,"class":44},"BonusBio Group Ltd","INDUSTRY",6,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":4},"100477471","phase-3-a-controlled-study-to-evaluate-the-efficacy-of-allogeneic-mesencure-for-the-treatment-of-patients-with-ards-100477471","NCT05497401","A Controlled Study to Evaluate the Efficacy of Allogeneic MesenCure for the Treatment of Patients With ARDS","Inclusion Criteria:\n\n1. Patients are able and agree to sign informed consent form before any study-specific procedure.\n2. Males or females, age range 18-80.\n3. Documented ARDS\n4. RA-O2 Saturation of ≤93% and\u002For Evidence of COVID19-related pulmonary infiltrates on chest X-ray\u002Fthoracic tomography\n5. Stable hemodynamic condition (blood pressure of systolic \\\u003C180mm Hg and diastolic \\\u003C110mm Hg)\n\nExclusion Criteria:\n\nGeneral:\n\n1. Pregnant or breast-feeding females.\n2. History of drug abuse.\n3. Heavy smokers (above 2 packages a day).\n4. Subjects incapable of giving consent.\n\nBackground medical conditions:\n\n1. Known history of any significant medical disorder, which in the investigator's judgment contraindicates the subject's participation.\n2. History of advanced congestive heart failure or active acute myocardial infarction (AMI), renal failure (estimated GFR of \\\u003C30 ml\u002Fmin\u002F1.73 m2 at screening), or hepatic disease (hepatic insufficiency classified as Child-Pugh B or C).\n3. Known autoimmune diseases.\n4. Received any investigational drug within 30 days prior to screening day (Visit 1) (Remdesivir is not considered investigational, and is not an exclusion criteria).\n5. Immunocompromised condition from any reason, at screening.\n6. Abnormal clinically significant laboratory test findings, as per the investigator's judgment.\n7. Poorly controlled diabetic subjects (HbA1c \\> 9%).\n8. Known active lung malignancy.\n\nConcomitant treatment:\n\n1. Currently treated with Immunosuppressive agents other than corticosteroids used for treating COVID19.\n2. Treatment for cancer (i.e. chemotherapy or radiotherapy treatment) within the last 12 months.\n\nHypersensitivity:\n\n1. Known history of hypersensitivity to Dextran-40.\n2. Known history of hypersensitivity to Human Serum Albumin.",{"count":53,"type":21},300,[55],"PHASE3","The efficacy of the allogeneic cell-therapy product MesenCure in addition to standard of care will be evaluated in comparison to placebo control in 300 moderate to severe Covid patients",[58],"ARDS","NOT_YET_RECRUITING","2025-08-06",{"date":62,"type":37},"2025-08-11",{"date":64,"type":21},"2026-04",{"date":66,"type":21},"2028-10",{"name":43,"class":44},""]